Public comments on docket FDA-2026-N-10429 are due November 20, 2026, the date the Food and Drug Administration set when it asked for outside input on how to run early-phase clinical trials of ibogaine. The request, announced October 5, covers study design and patient populations, dose selection and escalation, safety monitoring for cardiac and neurologic events, and the ethical oversight of volunteers, including informed consent.
Ibogaine, a psychoactive compound extracted from the roots of an African shrub, remains in the first and most tightly restricted schedule of the Controlled Substances Act, with no approved medical use in the United States. The FDA notice does not approve a trial, a dose or an indication. It asks the public to say how a first human study should be built, and every comment filed to the docket before the deadline becomes part of the record the agency can draw on.
Four questions in the FDA’s request
The FDA announcement quotes Michael Davis, M.D., Ph.D., director of the agency’s Center for Drug Evaluation and Research: “Patients facing serious conditions that have not responded to existing treatments deserve rigorous scientific investigation of promising new approaches.” The request itself is narrower than that sentence. Its dose question is anchored to a specific parameter: a starting dose not exceeding 10 milligrams per kilogram of body weight, which the agency presents as a design parameter on which it wants comment rather than an approved or recommended dose.
Comments go to the docket through Regulations.gov or by mail to the agency’s Dockets Management Staff at 5630 Fishers Lane in Rockville, Maryland. The announcement describes a 45-day comment period measured from Federal Register publication, which is how a window opened this week closes on November 20. Electronic submission requires the docket number, FDA-2026-N-10429, on every comment.
Cardiac risk and the QT problem
Heart rhythm is the reason the monitoring question comes first among the risks. The National Institute on Drug Abuse says ibogaine use has been associated with long QT syndrome, a disorder in which the electrical impulses that control heartbeats function irregularly, citing an analysis of studies from 2015 through 2020. NIDA director Nora Volkow has flagged cardiac risk as a continuing barrier to approval, according to an August 26 report that also ties documented arrhythmias to the halt of U.S. research in the 1990s.
The FDA’s request names safety monitoring for cardiac and neurologic events as one of its four areas, which makes the docket the place where sponsors, cardiologists and addiction physicians can put forward specific monitoring approaches before any protocol is filed. The announcement itself sets out the questions and does not prescribe answers; what the agency ultimately expects in a protocol will depend on what the record contains once comments close.
A federal push that started in April
The docket sits inside a broader federal turn toward psychedelics. President Trump signed Executive Order 14401, Accelerating Medical Treatments for Serious Mental Illness, on April 18, 2026. It states that “psychedelic drugs, including ibogaine compounds, show potential in clinical studies to address serious mental illnesses,” directs the Department of Health and Human Services to allocate at least $50 million to support state psychedelic programs, and tells the FDA to award National Priority Vouchers to psychedelic drugs with Breakthrough Therapy designation.
The FDA’s announcement identifies two populations that HHS is prioritizing for federally supported research: adults with opioid use disorder and adults with post-traumatic stress disorder. NIDA is funding ibogaine research for potential treatment of opioid use disorder, and the FDA says an early-phase study of noribogaine hydrochloride, an ibogaine derivative, has previously been approved for alcohol use disorder.
Supply is a quieter constraint. The Drug Enforcement Administration’s 2026 aggregate production quota allows 210 grams of ibogaine to be manufactured in the United States for the whole year. At the 10 mg/kg starting level the FDA mentions, a 70-kilogram volunteer would receive 700 milligrams, so 210 grams would cover roughly 300 doses of that size across every U.S. manufacturer and all uses combined, a ceiling that frames how large any early trial could be. Texas has committed $50 million to FDA-supervised ibogaine trials through Senate Bill 2308, and DemeRx’s oral formulation, DMX-1001, has had an investigational new drug application accepted, with Phase 2 trials anticipated in 2027, according to the same August report. CP24 reported in September that the FDA accepted an investigational new drug application for an ibogaine derivative in April and has issued national priority vouchers for certain psychedelic drugs.
Until the November 20 deadline, docket FDA-2026-N-10429 is where the agency has asked for challenges to its own framing, and the 10 mg/kg starting-dose parameter is the most concrete number on the table for commenters to confirm, lower or contest.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
- Security experts still urge phone owners to switch off one location-tracking setting
- The FBI warns a new phishing trick can hijack your account without your password
- The NSA says three phone features should be off whenever you aren’t using them
- Hawaii’s magnitude 6.0 Kona earthquake is now a federal major disaster
